跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/PER-053-14
PER-053-14已完成未知

A 52-WEEK, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRALOKINUMAB IN ADULTS AND ADOLESCENTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROID PLUS LONG-ACTING β2-AGONIST (D2210C00007)

ASTRAZENECA - PERU,0 个研究点目标入组 101 人开始时间: 2015年1月15日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
101
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
12 至 75（—）

入选标准

  • •For inclusion in the study, subjects should fulfil the following criteria:
  • •1.Provision of informed consent prior to any study specific procedures for subjects who are at, or over the age of majority (as per local law). For subjects less than the age of majority, in addition to the subject providing informed assent, the subject’s legal guardian must also provide their informed consent.
  • •2.Female and male aged from 12 to 75 years, inclusively. A subject will need to be 12 years of age at the time of enrolment. Subjects at the upper end of the age spectrum will need to be 75 years of age at the time of randomization. (For those countries where local regulations permit enrolment of adults only, subject recruitment will be restricted to those who are ≥18 years).
  • •3.Women of childbearing potential (WOCBP) must use a highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control includes: true sexual abstinence, a vasectomised sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device/system (IUD/IUS), Depo-Provera™ injections, oral contraceptive, and Evra Patch ™ or Nuvaring™. WOCBP must agree to use highly effective method of birth control, as defined above, from enrolment, throughout the study duration and within 16 after last dose of investigational product (IP), and have negative serum pregnancy test result at Visit 1.
  • •a.Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postemenopausal if they have been amenorrheic for 12 months prior to the planned date of randomization without an alternative medical cause. The following age-specific requirements apply:
  • •i.Women <50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range.
  • •ii.Women ≥50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
  • •4.Weight of ≥30 and <150 kg at enrolment (Visit 1). For adults (≥ 18 years of age) the weight must not be below 40 kg.
  • •5.Documented physician-diagnosed asthma for at least 12 months prior to enrolment with the subject having received an asthma controller regimen requiring treatment with medium-to-high dose ICS for at least 6 of the 12 months prior to enrolment (Visit 1). In addition, subjects must have used physician prescribed ICS (at a total daily dose ≥500μg fluticasone propionate via dry powder inhaler or equivalent delivered dose) that has been taken at a stable dose for at least 3 months prior to enrolment.
  • •6.Documented treatment with ICS at a total daily dose corresponding to ≥500μg fluticasone propionate dry powder formulation equivalents) and a LABA for at least 3 months prior to Visit 1. The ICS and LABA can be parts of a combination product, or given by separate inhalers.
  • •7.In order to aid the assessment, ICS equivalents for high-dose and moderate-dose fluticasone propionate dry powder, as published by the Global Initiative for Asthma (GINA 2012) guidelines, are presented in Appendix F. The Investigator will assess the subject’s total dail

排除标准

  • •1.Enfermedad pulmonar clinicamente importante excepto asma (por ejemplo, infeccion pulmonar activa, EPOC, bronquiectasia, fibrosis pulmonar, fibrosis quistica, sindrome de hipoventilacion asociado con la obesidad, cancer de pulmon, deficiencia de alfa-1 antitripsina, y disquinesia ciliar primaria) o haber tenido alguna vez un diagnostico de enfermedad pulmonar o sistemica, excepto asma, que esta asociada con un aumento en el recuento de eosinofilos perifericos (por ejemplo, aspergilosis/micosis broncopulmonar alergica/, sindrome de Churg-Strauss, sindrome hipereosinofilico).
  • •2.Cualquier trastorno, incluyendo pero no limitado a, cardiovascular, gastrointestinal, hepatico, renal, neurologico, musculoesqueletico, infeccioso, endocrino, metabolico, hematologico, psiquiatrico, o alteracion fisica importante que no este estable segun la opinion del investigador y que podria:
  • •Afectar la seguridad del sujeto durante todo el estudio
  • •Influir en los hallazgos de los estudios o sus interpretaciones
  • •Impedir la capacidad del sujeto de completar todo el estudio
  • •3.Antecedentes conocidos de alergia o reaccion a cualquier componente de la formulacion del IP.
  • •4.Antecedentes de anafilaxia luego de cualquier terapia biologica
  • •5.Infeccion parasitaria por helmintos diagnosticada dentro de los 6 meses previos a la fecha de obtencion del consentimiento o asentimiento informado que no ha sido tratada con la terapia que es el estandar de atencion o que no logro responder a esta.
  • •6.Antecedentes de infeccion clinicamente significativa, incluso infecciones agudas de las vias respiratorias superiores o inferiores, que requiere antibioticos o antivirales dentro de los 30 dias previos a la fecha de obtencion del consentimiento o asentimiento informado o durante el periodo de pre-inclusion.
  • •7.Tuberculosis que requiere tratamiento dentro de los 12 meses previos al enrolamiento (Visita 1).
  • •8.Cualquier hallazgo anormal clinicamente significativo en el examen fisico, signos vitales, dECG, hematologia, bioquimica clinica, o analisis de orina durante el periodo de pre-inclusion, que a criterio del investigador, puede poner en riesgo al paciente a causa de su participacion en el estudio, o puede influir en los resultados del estudio, o en la capacidad que tenga el sujeto de completar todo el estudio.
  • •9.Antecedentes de alcoholismo o drogadiccion cronica dentro de los 12 meses de la visita de enrolamiento, o una afeccion asociada con un escaso cumplimiento segun el criterio del Investigador.
  • •10.Resultado positivo en la serologia del antigeno de superficie de la hepatitis B o anticuerpos del virus de la hepatitis C. Se permite el enrolamiento de sujetos con antecedentes de vacunacion contra la hepatitis B sin antecedentes de hepatitis B.
  • •11.Antecedentes de cualquier trastorno de inmunodeficiencia primaria conocida que incluye una prueba positiva del virus de inmunodeficiencia humana (VIH) en el enrolamiento, o que el sujeto este tomando medicamentos antirretrovirales segun lo determinado por la historia clinica y/o el informe verbal del sujeto.
  • •12.Tabaquismo actual (se debe haber dejado de fumar por ≥ 3 meses antes del enrolamiento) o antecedentes de tabaquismo de ≥ 10 paquetes-año (un paquete-año = 20 cigarrillos fumados por dia durante 1 año).
  • •13.Antecedentes oncologicos:
  • •Los sujetos que hayan tenido carcinoma de celulas basales, carcinoma localizado de celulas escamosas de la piel o carcinoma

研究者

发起方
ASTRAZENECA - PERU,

相似试验

已完成
不适用
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLEDUMMY, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY OF FEVIPIPRANT ONCE DAILY PLUS STANDARD-OF-CARE (SOC) FORREDUCTION OF SYSTEMIC CORTICOSTEROIDS (ORAL AND PARENTERAL) USE IN PATIENTS WITH SEVERE ASTHMA-J45J45
PER-050-18OVARTIS BIOSCIENSES PERU S.A.,17
已完成
不适用
SAFETY AND EFFICACY STUDY OF QVM149 IN ASTHMATIC PATIENTS
PER-024-16OVARTIS BIOSCIENSES PERU S.A.,26
招募中
不适用
A 52-WEEK, DOUBLE-BLIND, RANDOMISED, MULTI-CENTRE, PARALLEL-GROUP,PHASE IIISTUDY IN PATIENTS 12 YEARS AND OLDER WITH ASTHMA, EVALUATING THE EFFICACY ANDSAFETY OF SYMBICORT® (BUDESONIDE/FORMOTEROL) TURBUHALER® 160/4.5 &#956;G ‘ASNEEDED’ COMPARED WITH TERBUTALINE TURBUHALER® 0.4 MG ‘AS NEEDED’ AND WITHPULMICORT® (BUDESONIDE) TURBUHALER® 200 &#956;G TWICE DAILY PLUS TERBUTALINETURBUHALER® 0.4 MG ‘AS NEEDED’
PER-035-14ASTRAZENECA - PERU,287
已完成
不适用
A 52-WEEK, DOUBLE-BLIND, RANDOMISED, MULTI-CENTRE, PHASE III, PARALLEL-GROUP STUDY IN PATIENTS 12 YEARS AND OLDER WITH ASTHMA, EVALUATING THE EFFICACY AND SAFETY OF SYMBICORT (BUDESONIDE/FORMOTEROL) TURBUHALER 160/4.5 &#956;G ‘AS NEEDED’ COMPARED WITH PULMICORT (BUDESONIDE) TURBUHALER 200 &#956;G TWICE DAILY PLUS TERBUTALINE TURBUHALER 0.4 MG ‘AS NEEDED’-J45J45
PER-059-14ASTRAZENECA - PERU,213
进行中（未招募）
1 期
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
EUCTR2010-023417-54-SKGlaxoSmithKline R&D Ltd